Akebia reports Q2 2026 results, VOICE interim data, and new ebribafusp trial
Vafseo revenue rose to $21.3 million as Akebia started a Phase 2 basket trial in three rare kidney diseases and cited positive interim safety data from the VOICE trial.
Akebia Therapeutics reported second quarter 2026 results on August 5, 2026, covering the period ended June 30, 2026.
The company said a planned interim analysis of the VOICE trial, which enrolled 2,116 patients, met its predefined stopping criteria, showing a statistically significant improved safety outcome for patients on Vafseo dosed three times weekly compared with erythropoiesis stimulating agents on a hierarchical composite endpoint of all-cause mortality and hospitalization, driven by fewer hospitalizations.1 Akebia said these results replicated the safety outcomes seen in a post-hoc win statistics analysis of the Phase 3 INNO2VATE trial.1 U.S. Renal Care, which ran the VOICE trial with Akebia, expects to submit the data for presentation at an upcoming medical meeting.1
In pipeline news, Akebia said in August that it initiated a Phase 2 open-label basket trial of ebribafusp, a next-generation complement inhibitor formerly known as AKB-097 and ADX-097, in patients with IgA nephropathy, lupus nephritis, or C3 glomerulopathy, with plans to enroll up to 30 patients dosed subcutaneously once weekly.1 The trial is open-label, and Akebia expects to report initial data in 2027.1 Separately, enrollment continues in the company's Phase 2 trial of praliciguat in FSGS.1
On intellectual property, Akebia said in June it added a new Orange Book-listed patent for Vafseo expiring in June 2034 and became eligible for a five-year patent term extension on a composition-of-matter patent that would push that patent's expiration to mid-2032, bringing its Vafseo portfolio to 14 Orange Book-listed patents with expirations out to 2036.1
On finances, cash and cash equivalents were approximately $155.5 million as of June 30, 2026, down from $162.6 million at the end of the first quarter.1 The company said existing cash, expected product, royalty, supply and license revenue, and a planned refinancing of its senior secured term loan facility should fund its operating plan for at least two years.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.